297 related articles for article (PubMed ID: 32418181)
1. Recommendations for the measurement of the QT interval during the use of drugs for COVID-19 infection treatment. Updatable in accordance with the availability of new evidence.
Asensio E; Acunzo R; Uribe W; Saad EB; Sáenz LC
J Interv Card Electrophysiol; 2020 Nov; 59(2):315-320. PubMed ID: 32418181
[TBL] [Abstract][Full Text] [Related]
2. QT prolongation in a diverse, urban population of COVID-19 patients treated with hydroxychloroquine, chloroquine, or azithromycin.
Hsia BC; Greige N; Quiroz JA; Khokhar AS; Daily J; Di Biase L; Ferrick KJ; Fisher JD; Krumerman A
J Interv Card Electrophysiol; 2020 Nov; 59(2):337-345. PubMed ID: 32654098
[TBL] [Abstract][Full Text] [Related]
3. Effect of Chloroquine, Hydroxychloroquine, and Azithromycin on the Corrected QT Interval in Patients With SARS-CoV-2 Infection.
Saleh M; Gabriels J; Chang D; Soo Kim B; Mansoor A; Mahmood E; Makker P; Ismail H; Goldner B; Willner J; Beldner S; Mitra R; John R; Chinitz J; Skipitaris N; Mountantonakis S; Epstein LM
Circ Arrhythm Electrophysiol; 2020 Jun; 13(6):e008662. PubMed ID: 32347743
[TBL] [Abstract][Full Text] [Related]
4. QTc evaluation in COVID-19 patients treated with chloroquine/hydroxychloroquine: A letter to the editor.
Danjuma MI; Sinha U; Fatima H; Mohamed MFH; Nathoe H
Eur J Clin Invest; 2020 Nov; 50(11):e13407. PubMed ID: 32918829
[No Abstract] [Full Text] [Related]
5. COVID-19 and (hydroxy)chloroquine-azithromycin combination: Should we take the risk for our patients?
Javelot H; El-Hage W; Meyer G; Becker G; Michel B; Hingray C
Br J Clin Pharmacol; 2020 Jun; 86(6):1176-1177. PubMed ID: 32350872
[No Abstract] [Full Text] [Related]
6. "Off-label" use of hydroxychloroquine, azithromycin, lopinavir-ritonavir and chloroquine in COVID-19: A survey of cardiac adverse drug reactions by the French Network of Pharmacovigilance Centers.
Gérard A; Romani S; Fresse A; Viard D; Parassol N; Granvuillemin A; Chouchana L; Rocher F; Drici MD;
Therapie; 2020; 75(4):371-379. PubMed ID: 32418730
[TBL] [Abstract][Full Text] [Related]
7. Cardiac safety of off-label COVID-19 drug therapy: a review and proposed monitoring protocol.
Naksuk N; Lazar S; Peeraphatdit TB
Eur Heart J Acute Cardiovasc Care; 2020 Apr; 9(3):215-221. PubMed ID: 32372695
[TBL] [Abstract][Full Text] [Related]
8. QT Interval Control to Prevent Torsades de Pointes during Use of Hydroxychloroquine and/or Azithromycin in Patients with COVID-19.
Wu TC; Sacilotto L; Darrieux FCDC; Pisani CF; Melo SL; Hachul DT; Scanavacca M
Arq Bras Cardiol; 2020 Jun; 114(6):1061-1066. PubMed ID: 32638906
[No Abstract] [Full Text] [Related]
9. QTc evaluation in COVID-19 patients treated with chloroquine/hydroxychloroquine.
Monzani A; Genoni G; Scopinaro A; Pistis G; Kozel D; Secco GG
Eur J Clin Invest; 2020 Jun; 50(6):e13258. PubMed ID: 32356580
[No Abstract] [Full Text] [Related]
10. The QT interval in patients with COVID-19 treated with hydroxychloroquine and azithromycin.
Chorin E; Dai M; Shulman E; Wadhwani L; Bar-Cohen R; Barbhaiya C; Aizer A; Holmes D; Bernstein S; Spinelli M; Park DS; Chinitz LA; Jankelson L
Nat Med; 2020 Jun; 26(6):808-809. PubMed ID: 32488217
[No Abstract] [Full Text] [Related]
11. Concentration-dependent mortality of chloroquine in overdose.
Watson JA; Tarning J; Hoglund RM; Baud FJ; Megarbane B; Clemessy JL; White NJ
Elife; 2020 Jul; 9():. PubMed ID: 32639233
[TBL] [Abstract][Full Text] [Related]
12. COVID-19 and cardiac arrhythmias: a global perspective on arrhythmia characteristics and management strategies.
Gopinathannair R; Merchant FM; Lakkireddy DR; Etheridge SP; Feigofsky S; Han JK; Kabra R; Natale A; Poe S; Saha SA; Russo AM
J Interv Card Electrophysiol; 2020 Nov; 59(2):329-336. PubMed ID: 32494896
[TBL] [Abstract][Full Text] [Related]
13. Experience With Hydroxychloroquine and Azithromycin in the Coronavirus Disease 2019 Pandemic: Implications for QT Interval Monitoring.
Ramireddy A; Chugh H; Reinier K; Ebinger J; Park E; Thompson M; Cingolani E; Cheng S; Marban E; Albert CM; Chugh SS
J Am Heart Assoc; 2020 Jun; 9(12):e017144. PubMed ID: 32463348
[TBL] [Abstract][Full Text] [Related]
14. QT interval evaluation associated with the use of hydroxychloroquine with combined use of azithromycin among hospitalised children positive for coronavirus disease 2019.
Tuncer T; Karaci M; Boga A; Durmaz H; Guven S
Cardiol Young; 2020 Oct; 30(10):1482-1485. PubMed ID: 32686633
[TBL] [Abstract][Full Text] [Related]
15. Ventricular arrhythmia risk due to chloroquine / hydroxychloroquine treatment for COVID-19: Should it be given.
Malviya A
Indian Heart J; 2020; 72(2):131-132. PubMed ID: 32534688
[No Abstract] [Full Text] [Related]
16. Incidence of arrhythmias and electrocardiographic abnormalities in symptomatic pediatric patients with PCR-positive SARS-CoV-2 infection, including drug-induced changes in the corrected QT interval.
Samuel S; Friedman RA; Sharma C; Ganigara M; Mitchell E; Schleien C; Blaufox AD
Heart Rhythm; 2020 Nov; 17(11):1960-1966. PubMed ID: 32621881
[TBL] [Abstract][Full Text] [Related]
17. QTc prolongation in COVID-19 patients treated with hydroxychloroquine, chloroquine, azithromycin, or lopinavir/ritonavir: A systematic review and meta-analysis.
Diaz-Arocutipa C; Brañez-Condorena A; Hernandez AV
Pharmacoepidemiol Drug Saf; 2021 Jun; 30(6):694-706. PubMed ID: 33772933
[TBL] [Abstract][Full Text] [Related]
18. QT Interval Prolongation Under Hydroxychloroquine/Azithromycin Association for Inpatients With SARS-CoV-2 Lower Respiratory Tract Infection.
Bun SS; Taghji P; Courjon J; Squara F; Scarlatti D; Theodore G; Baudouy D; Sartre B; Labbaoui M; Dellamonica J; Doyen D; Marquette CH; Levraut J; Esnault V; Bun SS; Ferrari E
Clin Pharmacol Ther; 2020 Nov; 108(5):1090-1097. PubMed ID: 32588427
[TBL] [Abstract][Full Text] [Related]
19. Effect of Hydroxychloroquine and Azithromycin on QT Interval Prolongation and Other Cardiac Arrhythmias in COVID-19 Confirmed Patients.
Eftekhar SP; Kazemi S; Barary M; Javanian M; Ebrahimpour S; Ziaei N
Cardiovasc Ther; 2021; 2021():6683098. PubMed ID: 33688374
[TBL] [Abstract][Full Text] [Related]
20. QT interval prolongation and torsade de pointes in patients with COVID-19 treated with hydroxychloroquine/azithromycin.
Chorin E; Wadhwani L; Magnani S; Dai M; Shulman E; Nadeau-Routhier C; Knotts R; Bar-Cohen R; Kogan E; Barbhaiya C; Aizer A; Holmes D; Bernstein S; Spinelli M; Park DS; Stefano C; Chinitz LA; Jankelson L
Heart Rhythm; 2020 Sep; 17(9):1425-1433. PubMed ID: 32407884
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
